Cargando…

N-arylpyrazole NOD2 agonists promote immune checkpoint inhibitor therapy

The characterization of microbiota mechanisms in health and disease has reinvigorated pattern recognition receptors as prominent targets for immunotherapy. Notably, our recent studies on Enterococcus species revealed peptidoglycan remodeling and activation of NOD2 as key mechanisms for microbiota en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Griffin, Matthew E., Tsukidate, Taku, Hang, Howard C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901186/ https://www.ncbi.nlm.nih.gov/pubmed/36747725 http://dx.doi.org/10.1101/2023.01.26.525573

Ejemplares similares

Small molecule modulators of immune pattern recognition receptors
por: Tsukidate, Taku, et al.
Publicado: (2023)

The Synergistic Potential of Combining PD-1/PD-L1 Immune Checkpoint Inhibitors with NOD2 Agonists in Alzheimer’s Disease Treatment
por: Ghareghani, Majid, et al.
Publicado: (2023)

Introducing chirality in halogenated 3-arylsydnones and their corresponding 1-arylpyrazoles obtained by 1,3-dipolar cycloaddition
por: Popa, Marcel Mirel, et al.
Publicado: (2020)

Primary mono- and bis-sulfonamides obtained via regiospecific sulfochlorination of N-arylpyrazoles: inhibition profile against a panel of human carbonic anhydrases
por: Krasavin, Mikhail, et al.
Publicado: (2017)

Microbial mechanisms to improve immune checkpoint blockade responsiveness
por: Griffin, Matthew E., et al.
Publicado: (2022)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

Synthesis, fungicidal activity, structure-activity relationships (SARs) and density functional theory (DFT) studies of novel strobilurin analogues containing arylpyrazole rings
por: Liu, Yuanyuan, et al.
Publicado: (2018)

Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy
por: Baumann, Daniel, et al.
Publicado: (2020)

Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune Potentiators
por: Guzelj, Samo, et al.
Publicado: (2022)

Immune checkpoint inhibitors in cancer therapy
por: Webb, Eika S., et al.
Publicado: (2018)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
por: Quilez, Alicia, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Cancer Therapy
por: Shiravand, Yavar, et al.
Publicado: (2022)

Translocation of bacterial NOD2 agonist and its link with inflammation
por: Kim, Oh Yoen, et al.
Publicado: (2009)

Synthesis and validation of click-modified NOD1/2 agonists
por: Bharadwaj, Ravi, et al.
Publicado: (2023)

Immune checkpoint inhibitors in clinical trials
por: Sharon, Elad, et al.
Publicado: (2014)

TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
por: Gonzalez, Caleb, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
por: Mahzari, Moeber, et al.
Publicado: (2015)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
por: Lee, Juwon, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Immune checkpoint inhibitor therapy for hepatocellular carcinoma
por: Ramai, Daryl, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
por: Basudan, Ahmed M.
Publicado: (2022)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Discovery of Desmuramylpeptide NOD2 Agonists with Single-Digit Nanomolar Potency
por: Guzelj, Samo, et al.
Publicado: (2022)

Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils
por: Zhou, Ziwei, et al.
Publicado: (2022)

Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy
por: Zurko, Joanna, et al.
Publicado: (2018)

New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses
por: Gutjahr, Alice, et al.
Publicado: (2020)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Rapid labelling and covalent inhibition of intracellular native proteins using ligand-directed N-acyl-N-alkyl sulfonamide
por: Tamura, Tomonori, et al.
Publicado: (2018)

Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma
por: Zhu, Chao, et al.
Publicado: (2021)

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy
por: Balakrishna, Pragathi, et al.
Publicado: (2017)

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
por: Botticelli, Andrea, et al.
Publicado: (2017)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Advances in immune checkpoint inhibitors for bone sarcoma therapy
por: Thanindratarn, Pichaya, et al.
Publicado: (2019)

Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
por: Frankel, Arthur E., et al.
Publicado: (2019)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

A decade of immune-checkpoint inhibitors in cancer therapy
por: Robert, Caroline
Publicado: (2020)

Molecular imaging biomarkers for immune checkpoint inhibitor therapy
por: van de Donk, Pim P, et al.
Publicado: (2020)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kko9j42n844ksbq647340732dj